Biotechnology

Elpis Biopharmaceuticals and Singapore General Hospital Enter Research Collaboration Agreement to Develop Next Generation Allogeneic CAR Technologies

Agreement focuses on advancing armored and bi-specific CAR-γδTs for AML and multiple myeloma LEXINGTON, Mass. and SINGAPORE, June 4, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announc...

2025-06-04 19:00 2439

Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan

MELBOURNE, Australia and KYOTO, Japan, June 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that it has established Telix Manufacturing Solutions (TMS) in Yokohama, Japan. Telix's first cyclotron facility in the Asia Pacific re...

2025-06-04 06:30 3677

ThinkCyte Unveils MorphoScan Cloud: A Versatile Cloud-Based Platform for AI-Driven Cell Morphology Data Analysis

TOKYO, June 3, 2025 /PRNewswire/ -- ThinkCyte, a life science company pioneering advanced AI-powered cell analysis and sorting technologies, today announced the pre-commercial launch of MorphoScan Cloud, its new cloud-based platform designed for flexible data access, faster processing, and advanc...

2025-06-03 23:34 1913

Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

* EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6.  * The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of p...

2025-06-03 14:00 2614

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical iso...

2025-06-02 09:00 2746

Medidata Debuts Protocol Optimization at ASCO, Leveraging AI to Transform the Study Experience

New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and delivers increased efficiencies for clinical trials  SINGAPORE, June 2, 2025 /PRNewswire/ -- Medidata , a Dassault Systèmes brand and leading provider of clinical...

2025-06-02 09:00 2084

Illuminating ctDNA-MRD: Gene Solutions' K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology

DA NANG, Vietnam, May 31, 2025 /PRNewswire/ -- May 9-11, 2025, Gene Solutions , a pioneer in AI-driven precision oncology hosted  K-CONNECT APAC 2025 , a pivotal summit unitingover 100 distinguished oncologists and molecular biologis...

2025-05-31 10:16 3959

Teddy Laboratory (GuanHe Pharmaceuticals) Signs Strategic Cooperation Agreement with LabConnect to Forge a New Landscape in Laboratory Services Collaboration

JOHNSON CITY, Tenn., May 30, 2025 /PRNewswire/ -- Teddy Laboratory, a subsidiary of Tigermed, officially signed a strategic cooperation agreement with LabConnect, LLC, a global leader in central laboratory services. The two parties will jointly build a full-chain laboratory service system covering...

2025-05-30 05:05 2190

Dx&Vx Accelerates Development of Universal COVID-19 Vaccine

* Emerging as a next-generation vaccine amidst global resurgence of COVID-19 * Expanding v arious pipelines other than universal COVID vaccine SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Bio-healthcare company Dx&Vx (DXVX) has officially announced the acceleration of its development progr...

2025-05-29 21:03 2053

Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025

SHANGHAI, May 29, 2025 /PRNewswire/ -- Rona Therapeutics, a global leading RNA therapy company, today announced preclinical data for its self-developed RNA interference (RNAi) therapy RN026 at the National Lipid Association (NLA) Annual Scientific Sessions. Preclinical studies revealed that the t...

2025-05-29 20:00 2004

tHIS ASEAN 2025 to Debut in Kuala Lumpur, Uniting Southeast Asia's Healthcare Powerhouses

KUALA LUMPUR, Malaysia, May 29, 2025 /PRNewswire/ -- The Health Industry Series - ASEAN (tHIS ASEAN 2025), a groundbreaking event aimed at integrating healthcare resources across Southeast Asia, is set to take place in Kuala Lumpur during June 9-11. Co-located with the APHM International Healthca...

2025-05-29 19:22 2579

Metabolon's Untargeted Metabolomics Services Used for Landmark Study Linking a Western Dietary Pattern During Pregnancy to Neurodevelopment Disorders

Metabolomic profiling uncovered how maternal diet and metabolism may contribute to the risk of ADHD and autism in children MORRISVILLE, N.C., May 28, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, di...

2025-05-28 21:00 1705

EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

PROVIDENCE, R.I., May 28, 2025 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, is pleased to announce the appointment ofVibha Jawa, PhD, FAAPS as Chief Scientific Officer. Dr. Jawa succeeds EpiVax founder and Executive Chairw...

2025-05-28 14:13 2209

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma

* EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets a tumour-specific N-glycosylated epitope on both CEACAM5 and CEACAM6.  * The Fast Track Designation highlights the potential of EBC-129 to address critical unmet needs ...

2025-05-28 14:00 1935

Exclusive Global 20 Seats, China's Sole One! KT-939 Was Successfully Selected for 2025 NYSCC Inspiration Hive Zone

SUZHOU, China, May 28, 2025 /PRNewswire/ -- In the newly announced entry list of the Inspiration Hive zone at the 2025 New York Society of Cosmetic Chemists (NYSCC) exhibition, Kintor's innovative ingredient KT-939 has been selected as the only "Chinese Ingredient" among the numerous global ones....

2025-05-28 11:08 2043

Announcement of The Shaw Laureates 2025

HONG KONG, May 27, 2025 /PRNewswire/ --  The Shaw Laureates 2025 (from left to right): John Richard Bond and George Efstathiou, The Shaw Prize in Astronomy; Wolfgang Ba...

2025-05-27 19:36 2522

May 19: World Inflammatory Bowel Disease Day | Healthy Gut, Happy Life

SHENZHEN, China, May 26, 2025 /PRNewswire/ -- May 19 is designated as World Inflammatory Bowel Disease (IBD) Day, aimed at raising public awareness of IBD patients and improving their quality of life and medical care. The European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA),...

2025-05-26 21:24 2047

Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC

SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the Chi...

2025-05-26 12:15 2485

Chula Researchers Culture "Global-Warming Resistant Corals" for the Survival of Marine Ecosystems

BANGKOK, May 26, 2025 /PRNewswire/ -- Researchers at Chulalongkorn University 's Aquatic Resources Research Institute  have developed innovative methods to help corals adapt to global warming. Through artificial inseminati...

2025-05-26 10:59 2427

Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting

* Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented. * These data highlight elacestrant's potential ro...

2025-05-23 18:07 3767
1 ... 16171819202122 ... 186